Business Description
Syros Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US87184Q2066
Description
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.97 | |||||
| Equity-to-Asset | -0.13 | |||||
| Debt-to-Equity | -5.42 | |||||
| Debt-to-EBITDA | -0.66 | |||||
| Altman Z-Score | -15.51 | |||||
| Beneish M-Score | -7.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -52.5 | |||||
| 3-Year EBITDA Growth Rate | 31.4 | |||||
| 3-Year EPS without NRI Growth Rate | 37.6 | |||||
| 3-Year FCF Growth Rate | 33.5 | |||||
| 3-Year Book Growth Rate | -66.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 22.75 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.51 | |||||
| 9-Day RSI | 29.7 | |||||
| 14-Day RSI | 30.2 | |||||
| 6-1 Month Momentum % | -95.11 | |||||
| 12-1 Month Momentum % | -95.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.25 | |||||
| Quick Ratio | 2.25 | |||||
| Cash Ratio | 2.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -67.6 | |||||
| Shareholder Yield % | 33.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -28892.23 | |||||
| Net Margin % | -25340.67 | |||||
| FCF Margin % | -25920.73 | |||||
| ROE % | -967.58 | |||||
| ROA % | -76.13 | |||||
| ROIC % | -324.04 | |||||
| ROC (Joel Greenblatt) % | -490.78 | |||||
| ROCE % | -94.93 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.61 | |||||
| EV-to-EBIT | -0.08 | |||||
| EV-to-EBITDA | -0.08 | |||||
| EV-to-Revenue | 19.16 | |||||
| EV-to-Forward-Revenue | 26.86 | |||||
| EV-to-FCF | -0.07 | |||||
| Earnings Yield (Greenblatt) % | -1254.56 | |||||
| FCF Yield % | -1846.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Syros Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.386 | ||
| EPS (TTM) ($) | -3.07 | ||
| Beta | 0.73 | ||
| Volatility % | 217.05 | ||
| 14-Day RSI | 30.2 | ||
| 14-Day ATR ($) | 0.081475 | ||
| 20-Day SMA ($) | 0.237645 | ||
| 12-1 Month Momentum % | -95.84 | ||
| 52-Week Range ($) | 0.183 - 8.0965 | ||
| Shares Outstanding (Mil) | 26.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Syros Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Syros Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Syros Pharmaceuticals Inc Frequently Asked Questions
What is Syros Pharmaceuticals Inc(LTS:0LC7)'s stock price today?
The current price of LTS:0LC7 is $0.21. The 52 week high of LTS:0LC7 is $8.10 and 52 week low is $0.18.
When is next earnings date of Syros Pharmaceuticals Inc(LTS:0LC7)?
The next earnings date of Syros Pharmaceuticals Inc(LTS:0LC7) is 2025-03-27 Est..
Does Syros Pharmaceuticals Inc(LTS:0LC7) pay dividends? If so, how much?
Syros Pharmaceuticals Inc(LTS:0LC7) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers